Psoriasis
From the Journals
Drug survival study looks at what lasts longest in RA, axSpA, PsA, and psoriasis
Survival rates were highest for rituximab in rheumatoid arthritis and golimumab in axial spondyloarthritis in a study of two Danish registries.
From the Journals
One-third of psoriatic arthritis patients could have metabolic syndrome, data analysis finds
The results highlight the need for proper assessment of body weight and cardiovascular risk factors in patients with PsA at the onset of disease...
Commentary
An Update on JAK Inhibitors in Skin Disease
In this editorial, we focus on recent trials of JAK inhibitors tested in patients with atopic dermatitis, including topical RUX, as well as oral...
Latest News
How to make the most of your time with psoriasis patients
Patients have a long-term battle to get clear, and spending a little longer on the initial visit “pays a lot of dividends.”
Case Reports
Concurrent Atopic Dermatitis and Psoriasis Vulgaris: Implications for Targeted Biologic Therapy
We describe a patient with psoriasis that was well controlled on secukinumab who developed severe atopic dermatitis that improved with dupilumab...
Commentary
Just Like Rock and Roll, Topical Medications for Psoriasis Are Here to Stay
Coupled with this myriad of fundamental science is the emergence of newer therapies that are more directly targeting specific disease states and...
Original Research
Adjunctive Use of Halobetasol Propionate–Tazarotene in Biologic-Experienced Patients With Psoriasis
In this study, we assessed the effectiveness and safety of adjunctive halobetasol propionate (HP) 0.01%–tazarotene (TAZ) 0.045% lotion in adult...
Case Reports
Guttate Psoriasis Following COVID-19 Infection
We describe the case of a patient who experienced a moderate psoriatic flare 3 weeks after diagnosis of SARS-CoV-2 infection.
Case Reports
Severe Acute Systemic Reaction After the First Injections of Ixekizumab
Acute onycholysis (within 72 hours) is a rare side effect of ixekizumab.
Latest News
A dermatologist-led model for CVD prevention in psoriasis may be feasible
The researchers see their findings as an early but promising step in finding better models to improve cardiovascular outcomes for patients with...
From the Journals
More frequent secukinumab dosing found to benefit overweight psoriasis patients
“The need for individualized treatment in psoriasis is very real,” Dr. Raj Chovatiya said.